Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 48 articles:
HTML format
Text format



Single Articles


    October 2018
  1. CHEN WY, Zeng T, Wen YC, Yeh HL, et al
    Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
    Cancer Lett. 2018 Oct 9. pii: S0304-3835(18)30610.
    PubMed     Text format     Abstract available


    September 2018
  2. NIU Y, Guo C, Wen S, Tian J, et al
    ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis.
    Cancer Lett. 2018 Sep 15. pii: S0304-3835(18)30575.
    PubMed     Text format     Abstract available


  3. RUSSO JW, Liu X, Ye H, Calagua C, et al
    Phosphorylation of Androgen Receptor Serine 81 is Associated with its Reactivation in Castration-Resistant Prostate Cancer.
    Cancer Lett. 2018 Sep 11. pii: S0304-3835(18)30569.
    PubMed     Text format     Abstract available


  4. WANG S, Ekoue DN, Raj GV, Kittler R, et al
    Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer.
    Cancer Lett. 2018 Sep 11. pii: S0304-3835(18)30565.
    PubMed     Text format     Abstract available


  5. DELLIAUX C, Tian TV, Bouchet M, Fradet A, et al
    TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases.
    Cancer Lett. 2018 Sep 7. pii: S0304-3835(18)30551.
    PubMed     Text format     Abstract available


    August 2018
  6. DALAL K, Ban F, Li H, Morin H, et al
    Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.
    Cancer Lett. 2018 Aug 27. pii: S0304-3835(18)30528.
    PubMed     Text format     Abstract available


  7. MILLER DR, Tzeng CC, Farmer T, Keller ET, et al
    Novel CIL-102 Derivatives as Potential Therapeutic Agents for Docetaxel-Resistant Prostate Cancer.
    Cancer Lett. 2018 Aug 2. pii: S0304-3835(18)30503.
    PubMed     Text format     Abstract available


    June 2018
  8. CHANG YT, Lin TP, Tang JT, Campbell M, et al
    HOTAIR is a REST-regulated lncRNA that promotes neuroendocrine differentiation in castration resistant prostate cancer.
    Cancer Lett. 2018 Jun 23. pii: S0304-3835(18)30435.
    PubMed     Text format     Abstract available


    May 2018
  9. KANWAL R, Shukla S, Walker E, Gupta S, et al
    Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics.
    Cancer Lett. 2018 May 15. pii: S0304-3835(18)30339.
    PubMed     Text format     Abstract available


  10. ABISOYE-OGUNNIYAN A, Lin H, Ghebremedhin A, Salam A, et al
    Transcriptional Repressor Kaiso Promotes Epithelial to Mesenchymal Transition and Metastasis in Prostate Cancer through Direct Regulation of miR-200c.
    Cancer Lett. 2018 May 8. pii: S0304-3835(18)30319.
    PubMed     Text format     Abstract available


    April 2018
  11. SINGH SK, Lillard JW Jr., Singh R
    Title: Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer.
    Cancer Lett. 2018 Apr 17. pii: S0304-3835(18)30278.
    PubMed     Text format     Abstract available


  12. CHANG AC, Chen PC, Lin YF, Su CM, et al
    Osteoblast-secreted WISP-1 promotes adherence of prostate cancer cells to bone via the VCAM-1/integrin alpha4beta1 system.
    Cancer Lett. 2018 Apr 5. pii: S0304-3835(18)30254.
    PubMed     Text format     Abstract available


    March 2018
  13. OING C, Tennstedt P, Simon R, Volquardsen J, et al
    BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy.
    Cancer Lett. 2018 Mar 8. pii: S0304-3835(18)30196.
    PubMed     Text format     Abstract available


  14. UTTER M, Chakraborty S, Goren L, Feuser L, et al
    Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes.
    Cancer Lett. 2018;423:28-35.
    PubMed     Text format     Abstract available


    February 2018
  15. CHHABRA G, Singh CK, Ndiaye MA, Fedorowicz S, et al
    Prostate cancer chemoprevention by natural agents: Clinical evidence and potential implications.
    Cancer Lett. 2018 Feb 19. pii: S0304-3835(18)30158.
    PubMed     Text format     Abstract available


  16. LIN W, Luo J, Sun Y, Lin C, et al
    ASC-J9((R)) suppresses prostate cancer cell invasion via altering the sumoylation-phosphorylation of STAT3.
    Cancer Lett. 2018 Feb 6. pii: S0304-3835(18)30132.
    PubMed     Text format     Abstract available


  17. GRUNDEMANN C, Huber R
    Chemoprevention with isothiocyanates - From bench to bedside.
    Cancer Lett. 2018;414:26-33.
    PubMed     Text format     Abstract available


    January 2018
  18. MENG X, Vander Ark A, Daft P, Woodford E, et al
    Loss of TGF-beta signaling in osteoblasts increases basic-FGF and promotes prostate cancer bone metastasis.
    Cancer Lett. 2018 Jan 11. pii: S0304-3835(18)30040.
    PubMed     Text format     Abstract available


  19. LI X, Li J, Cai Y, Peng S, et al
    Hyperglycaemia-induced miR-301a promotes cell proliferation by repressing p21 and Smad4 in prostate cancer.
    Cancer Lett. 2018 Jan 10. pii: S0304-3835(18)30053.
    PubMed     Text format     Abstract available


  20. MITOBE Y, Takayama KI, Horie-Inoue K, Inoue S, et al
    Prostate cancer-associated lncRNAs.
    Cancer Lett. 2018 Jan 9. pii: S0304-3835(18)30034.
    PubMed     Text format     Abstract available


    December 2017
  21. LIU S, Li X, Lin Z, Su L, et al
    SEC-induced activation of ANXA7 GTPase suppresses prostate cancer metastasis.
    Cancer Lett. 2017;416:11-23.
    PubMed     Text format     Abstract available


  22. HU F, Zhao Y, Yu Y, Fang JM, et al
    Docetaxel-mediated autophagy promotes chemoresistance in castration-resistant prostate cancer cells by inhibiting STAT3.
    Cancer Lett. 2017;416:24-30.
    PubMed     Text format     Abstract available


  23. CHENG MA, Chou FJ, Wang K, Yang R, et al
    Androgen receptor (AR) degradation enhancer ASC-J9((R)) in an FDA-approved formulated solution suppresses castration resistant prostate cancer cell growth.
    Cancer Lett. 2017 Dec 1. pii: S0304-3835(17)30763.
    PubMed     Text format     Abstract available


    November 2017
  24. ZANG Y, Pascal LE, Zhou Y, Qiu X, et al
    ELL2 regulates DNA non-homologous end joining (NHEJ) repair in prostate cancer cells.
    Cancer Lett. 2017 Nov 24. pii: S0304-3835(17)30750.
    PubMed     Text format     Abstract available


  25. LEE C, Whang YM, Campbell P, Mulcrone PL, et al
    Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis.
    Cancer Lett. 2017;414:205-213.
    PubMed     Text format     Abstract available


  26. KUMAR S, Singh R, Malik S, Manne U, et al
    Prostate cancer health disparities: An immuno-biological perspective.
    Cancer Lett. 2017;414:153-165.
    PubMed     Text format     Abstract available


  27. KOLLURU V, Pal D, Papu John AMS, Ankem MK, et al
    Induction of Plac8 promotes pro-survival function of autophagy in cadmium-induced prostate carcinogenesis.
    Cancer Lett. 2017;408:121-129.
    PubMed     Text format     Abstract available


    October 2017
  28. GONZALEZ-CHAVARRIA I, Fernandez E, Gutierrez N, Gonzalez-Horta EE, et al
    LOX-1 activation by oxLDL triggers an epithelial mesenchymal transition and promotes tumorigenic potential in prostate cancer cells.
    Cancer Lett. 2017 Oct 26. pii: S0304-3835(17)30672.
    PubMed     Text format     Abstract available


    September 2017
  29. QIN F, Zhang Y, Liu J, Li H, et al
    SLC45A3-ELK4 functions as a long non-coding chimeric RNA.
    Cancer Lett. 2017;404:53-61.
    PubMed     Text format     Abstract available


  30. HOANG B, Ernsting MJ, Tang WS, Bteich J, et al
    Cabazitaxel-Conjugated Nanoparticles for Docetaxel-Resistant and Bone Metastatic Prostate Cancer.
    Cancer Lett. 2017 Sep 28. pii: S0304-3835(17)30582.
    PubMed     Text format     Abstract available


  31. EL-SAYED IY, Daher A, Destouches D, Firlej V, et al
    Extracellular vesicles released by mesenchymal-like prostate carcinoma cells modulate EMT state of recipient epithelial-like carcinoma cells through regulation of AR signaling.
    Cancer Lett. 2017 Sep 19. pii: S0304-3835(17)30560.
    PubMed     Text format     Abstract available


  32. BASHARI O, Redko B, Cohen A, Luboshits G, et al
    Discovery of peptide drug carrier candidates for targeted multi-drug delivery into prostate cancer cells.
    Cancer Lett. 2017 Sep 6. pii: S0304-3835(17)30535.
    PubMed     Text format     Abstract available


    August 2017
  33. DATTA A, Kim H, Lal M, McGee L, et al
    Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells.
    Cancer Lett. 2017 Aug 24. pii: S0304-3835(17)30507.
    PubMed     Text format     Abstract available


  34. CHEN J, Li L, Yang Z, Luo J, et al
    Androgen-deprivation therapy with enzalutamide enhances prostate cancer metastasis via decreasing the EPHB6 suppressor expression.
    Cancer Lett. 2017 Aug 18. pii: S0304-3835(17)30491.
    PubMed     Text format     Abstract available


  35. KANWAL R, Plaga AR, Liu X, Shukla GC, et al
    MicroRNAs in prostate cancer: Functional role as biomarkers.
    Cancer Lett. 2017 Aug 18. pii: S0304-3835(17)30488.
    PubMed     Text format     Abstract available


  36. AHMAD G, El Sadda R, Botchkina G, Ojima I, et al
    Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 inhibits prostate cancer stem cell-induced tumor growth.
    Cancer Lett. 2017;406:71-80.
    PubMed     Text format     Abstract available


  37. SHI X, Zhang X, Li J, Zhao H, et al
    PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.
    Cancer Lett. 2017 Aug 7. pii: S0304-3835(17)30465.
    PubMed     Text format     Abstract available


    July 2017
  38. LOGOZZI M, Angelini DF, Iessi E, Mizzoni D, et al
    Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients.
    Cancer Lett. 2017 Jul 8. pii: S0304-3835(17)30418.
    PubMed     Text format     Abstract available


    June 2017
  39. GAO F, Alwhaibi A, Sabbineni H, Verma A, et al
    Suppression of Akt1-beta-catenin pathway in advanced prostate cancer promotes TGFbeta1-mediated epithelial to mesenchymal transition and metastasis.
    Cancer Lett. 2017 Jun 7. pii: S0304-3835(17)30374.
    PubMed     Text format     Abstract available


  40. LI Q, Ye L, Xin Z, Wang M, et al
    FZD8, a target of p53, promotes bone metastasis in prostate cancer by activating canonical Wnt/beta-catenin signaling.
    Cancer Lett. 2017 Jun 7. pii: S0304-3835(17)30375.
    PubMed     Text format     Abstract available


    May 2017
  41. YAN F, Li X, Li N, Zhang R, et al
    Immunoproapoptotic molecule scFv-Fdt-tBid modified mesenchymal stem cells for prostate cancer dual-targeted therapy.
    Cancer Lett. 2017 May 18. pii: S0304-3835(17)30325.
    PubMed     Text format     Abstract available


  42. DILLY SJ, Clark AJ, Marsh A, Mitchell DA, et al
    A chemical genomics approach to drug reprofiling in oncology: Antipsychotic drug risperidone as a potential adenocarcinoma treatment.
    Cancer Lett. 2017;393:16-21.
    PubMed     Text format     Abstract available


    April 2017
  43. BRIZZOLARA A, Benelli R, Vene R, Barboro P, et al
    The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
    Cancer Lett. 2017 Apr 25. pii: S0304-3835(17)30285.
    PubMed     Text format     Abstract available


    March 2017
  44. LIN SJ, Chou FJ, Li L, Lin CY, et al
    Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
    Cancer Lett. 2017 Mar 31. pii: S0304-3835(17)30217.
    PubMed     Text format     Abstract available


  45. TAKAYAMA K, Inoue T, Narita S, Maita S, et al
    Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
    Cancer Lett. 2017 Mar 31. pii: S0304-3835(17)30216.
    PubMed     Text format     Abstract available


  46. O'MALLEY J, Kumar R, Kuzmin A, Pliss A, et al
    Lipid quantification by Raman microspectroscopy as a potential biomarker in prostate cancer.
    Cancer Lett. 2017 Mar 23. pii: S0304-3835(17)30199.
    PubMed     Text format     Abstract available


  47. GUO C, Yeh S, Niu Y, Li G, et al
    Targeting Androgen Receptor versus Targeting Androgens to suppress Castration Resistant Prostate Cancer.
    Cancer Lett. 2017 Mar 18. pii: S0304-3835(17)30195.
    PubMed     Text format     Abstract available


  48. KANG TS, Wang W, Zhong HJ, Dong ZZ, et al
    An anti-prostate cancer benzofuran-conjugated iridium(III) complex as a dual inhibitor of STAT3 and NF-kappaB.
    Cancer Lett. 2017 Mar 16. pii: S0304-3835(17)30180.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: